One randomized trial of CD34+ selection in rheumatoid arthritis (121) and a recent retrospective study assessing CD34+ selection in systemic sclerosis (122) did not show added benefit to overall or progression-free survival. This evidence concerns the gene CD34 and rheumatoid arthritis.